Clinical Trial

An Open-label Study of GB261 in Refractory Seropositive Systemic Lupus Erythematosus

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated April 25, 2025 (before its estimated June 2025 completion). Its status may not reflect the trial's current state.
Summary
The purpose of the study is to evaluate the safety and efficacy of CD20xCD3 T-cell engager (GB261) in patients with refractory seropositive systemic lupus erythematosus.
Trial Details
NCT Number NCT06945068
Lead Sponsor Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Conditions Systemic Lupus Erythematosus (SLE)
Enrollment 19 participants
Start Date 2025-06
Primary Completion 2025-06 (estimated)
Study Completion 2026-11-30 (estimated)
Updated on ClinicalTrials.gov 2025-04-25